Publications by authors named "A L Maslyanskiy"
Aim: To evaluate the long-term safety and efficacy of goflkicept treatment in patients with idiopathic recurrent pericarditis (IRP).
Materials And Methods: This report presents the interim analysis of an ongoing open-label extension (OLE) clinical trial of goflkicept in patients with IRP (NCT05673902), as a continuation of the core study (NCT04692766). The study assessed the frequency of pericarditis recurrence, time to recurrence after 12 and 60 weeks of goflkicept therapy, changes in C-reactive protein level, chest pain intensity, pericardial effusion size, and adverse events (AEs).
Article Synopsis
- - Adult-onset Still's disease (AOSD) is an inflammatory disorder that mainly involves abnormal immune responses, but the role of T and B cells in the disease is still not well understood.
- - A study with 7 AOSD patients and 15 healthy individuals used deep flow cytometry to analyze T- and B-cell subsets, revealing significant alterations in these immune cells in AOSD patients compared to controls.
- - Notable findings include decreased Th2 cells, changes in CD8+ T cell types, and a dramatic drop in a specific B cell subset (CD5+CD27-), suggesting the need for further research to understand these immune changes in AOSD.
Currently, multiple studies have indicated that CD8+ T lymphocytes play a role in causing damage to the exocrine glands through acinar injury in primary Sjögren's syndrome (pSS). The aim of this research was to assess the imbalance of circulating CD8+ T cell subsets. We analyzed blood samples from 34 pSS patients and 34 healthy individuals as controls.
View Article and Find Full Text PDFBackground: Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor-goflikicept in IRP.
View Article and Find Full Text PDFObjectives: Adult-onset Still's disease (AOSD) is increasingly viewed as autoinflammatory disease associated with the so-called inflammasomopathy. Proinflammatory cytokines, such as IL-18 and IL-1β, processed through the inflammasome machinery, play an important role in the pathogenesis of AOSD. AOSD is heterogenous, therefore there are two subtypes of the disease, systemic and articular, which probably imply different approaches for the treatment.
View Article and Find Full Text PDF